Monographs: Dosage forms: Specific monographs: Norethisterone enantate injection (Norethisteroni enantas injection)2022-01
Description. A clear, colourless or almost colourless, oily solution. Category. Contraceptive. Storage. Norethisterone enantate injection should be kept in a closed container, protected from light. Labelling. The oil used in the formulation should be indicated. Additional information. Strength in the current WHO Model List of Essential Medicines (EML): 200 mg/mL of Norethisterone enantate in 1 mL ampoule. Requirements Complies with the monograph for Parenteral preparations. Definition. Norethisterone enantate injection contains not less than 90.0% and not more than 110.0% of the amount of Norethisterone enantate (C27H 38O3) stated on the label. Identity tests
Bacterial endotoxins. Carry out the test as described under 3.4 Test for bacterial endotoxins; contains not more than 1.5 IU of endotoxin RS per mg of norethisterone enantate. Clarity and color of solution. Use 2.0 mL of the sample solution. This solution is clear and not more intensely coloured than reference solution Y3 or BY3, when compared as described under 1.11.2 Degree of coloration of liquids, Method I. Related substances. Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography, using a stainless steel column (5 cm x 2.0 mm) packed with particles of silica gel, the surface of which has been modified with chemically-bonded octadecylsilyl groups (3 μm). Use the following conditions for gradient elution:
Operate with a flow rate of 0.7 mL per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of 240 nm. Maintain the column at a temperature of 60 °C. Prepare the following solutions using as the diluent a mixture of 15 volumes of water R and 85 volumes of acetonitrile R. For solution (1), use solution (1) as described under "Assay". For solution (2), dilute 10.0 mL of solution (1) to 100.0 mL. Dilute 5.0 mL of this solution to 100.0 mL. For solution (3), dilute 10.0 mL of solution (2) to 50.0 mL. For solution (4), prepare a solution of norethisterone enantate for system suitability RS (containing norethisterone and impurity F) as described in the leaflet of the reference substance. For solution (5), use a suitably diluted solution of the oil used in the formulation. For solution (6), dissolve 20.0 mg benzyl benzoate R in 200.0 mL. Inject 10 μL each of solutions (3) and (4). The test is not valid unless, in the chromatogram obtained with solution (3), the signal-to-noise ratio of the peak due to norethisterone enantate is at least 10 and, in the chromatogram obtained with (4), the resolution between the peak due to impurity F (norethisterone caproate) and the peak due to norethisterone enantate is at least 3.0. Inject 10 μL each of solutions (1), (2), (4), (5) und (6). Use the chromatogram obtained with solutions (5) and (6) to identify any peak due to the oil used in the formulation and benzyl benzoate, if present. Norethisterone enantate is eluted with a retention time of about 24 minutes. In the chromatogram obtained with solution (1):
Assay. Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography, using the chromatographic conditions as described under "Related substances". Prepare the following solutions using as the diluent a mixture of 15 volumes of water R and 85 volumes of acetonitrile R. Weigh the contents of 10 ampoules, mix and determine the weight per milliliter (1.3.1) of the solution. For solution (1), transfer a weighed quantity of the mixed contents, nominally equivalent to 150.0 mg of Norethisterone enantate, into a 250 mL volumetric flask. Add about 200 mL of the diluent, sonicate for 5 minutes, allow to cool to room temperature and dilute to volume. No oil droplets should be visible. For solution (2), dissolve 60.0 mg of norethisterone enantate RS and dilute to 100.0 mL. Inject alternately 5 µL of each solutions (1) and (2) and record the chromatograms. Measure the areas of the peaks corresponding to norethisterone enantate obtained in the chromatograms of solutions (1) and (2) and calculate the percentage content of norethisterone enantate (C27H38O3) per mL of the injection solution, using the declared content of C27H38O3 in norethisterone enantate RS. Impurities The impurities limited by the requirements of this monograph include those listed in the monograph on Norethisterone enantate. |